# Braincool > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/braincool). ## Overview BrainCool is a Swedish medical device company focused on patient temperature management systems used in acute care and other hospital settings. Its product platform includes BrainCool/IQool, RhinoChill, and Cooral systems, each supported by related consumables and managed through separate subsidiaries. ## Products & services • BrainCool/IQool cooling system and pads • RhinoChill emergency cooling system • Cooral temperature management system • Single-use consumables for installed systems • Clinical study and product development support - **Cooling systems** (55%) — Reusable medical cooling devices sold for specific acute-care and oncology indications. - **Consumables** (35%) — Single-use cooling pads and related items used with installed systems. - **Distribution and system sales** (10%) — Partner-led sales of systems through distributors such as ZOLL in multiple markets. - BrainCool/IQool cooling system and pads - RhinoChill emergency cooling system - Cooral temperature management system - Single-use consumables for installed systems - Clinical study and product development support ## Customers BrainCool sells primarily to hospitals, emergency care providers, and healthcare systems that treat stroke, cardiac arrest, fever management, and chemotherapy-related indications. It also serves distributors and channel partners that market and place the systems in approved markets. Demand is driven by clinical need, regulatory approval, installed-base expansion, and recurring consumable usage. - **Hospital acute-care departments** (primary) — Buy BrainCool/IQool systems for in-hospital temperature management in neurological and cardiac indications. - **Emergency medical services** (secondary) — Use RhinoChill-type solutions for rapid cooling in pre-hospital or emergency settings. - **Oncology and infusion clinics** (secondary) — Use Cooral-related cooling solutions to reduce side effects of chemotherapy. - **Distribution partners** (primary) — Purchase and market systems in defined territories, expanding reach and regulatory coverage. - Hospitals treating stroke, cardiac arrest, and neurological fever - Oncology and infusion centers using cooling for chemotherapy support - Emergency care providers needing rapid pre-hospital cooling - Distributors such as ZOLL that sell into approved markets - Healthcare buyers seeking recurring consumables tied to installed systems ## Geography BrainCool is headquartered in Sweden and sells through a distributor-led model across Europe, the U.S., and selected Asian markets. The ZOLL agreement covers the U.S., Germany, Switzerland, and Austria, while additional Asian markets such as Thailand, Singapore, Indonesia, the Philippines, Malaysia, Taiwan, Pakistan, and Japan are being developed as approvals are obtained. Geography matters because market access depends on local regulatory clearance and distributor execution. - **Sweden** (20%) — Corporate base and likely development/administrative center - **United States** (35%) — Key market under the ZOLL distribution agreement - **Europe** (25%) — Includes Germany, Switzerland, and Austria - **Asia** (20%) — Markets under expansion and regulatory approval - Sweden is the corporate and development base - U.S. is a key commercial market through the ZOLL agreement - Germany, Switzerland, and Austria are covered by distributor channels - Asia expansion includes Thailand, Malaysia, Japan, and other markets - Regulatory approvals determine when deliveries can begin in each country ## Strategy BrainCool’s strategy is to expand its installed base through distributor partnerships while increasing recurring consumable sales from each deployed system. It also relies on clinical evidence, regulatory approvals, and product-specific commercialization to open new indications and new countries. The business is structured to scale through outsourced manufacturing and channel partners rather than heavy internal production capacity. - **Expand distributor-led commercialization** (short-term) — Channel partners extend market reach without building a large direct sales force. - **Increase installed base and consumables attach rate** (medium-term) — Each system sold can generate recurring demand for pads and other single-use items. - **Advance clinical and regulatory validation** (medium-term) — Medical adoption depends on evidence generation and country-by-country approvals. - Grow installed base to drive recurring consumable revenue - Use distributor partnerships to reach new countries efficiently - Secure regulatory approvals before market entry - Advance clinical evidence to support adoption and reimbursement - Outsource production to keep the operating model asset-light ## Risks BrainCool faces regulatory, clinical, and commercialization risk because each market and indication requires evidence, approvals, and distributor execution before sales can scale. As a medical device company with outsourced manufacturing and a consumables-linked model, it is also exposed to supplier dependence, product adoption risk, and demand variability tied to installed-base growth. Broader medtech risks include reimbursement pressure, competition from alternative therapies, and execution risk in international expansion. - **Regulatory approval delays** [high] — Deliveries in several markets cannot begin until local approvals are obtained. - **Clinical adoption and evidence risk** [high] — Hospital buyers rely on clinical studies and proven outcomes before broad adoption. - **Distributor concentration** [medium] — A significant portion of commercialization depends on partners such as ZOLL. - **Supplier and manufacturing dependence** [medium] — Production is subcontracted, so quality, lead times, and supply continuity matter. - Regulatory approvals can delay launches in new countries - Clinical evidence risk affects adoption and physician confidence - Distributor dependence can slow execution or reduce control - Outsourced manufacturing creates supplier and quality risk - Consumables revenue depends on installed-base growth ## Accounting BrainCool’s accounting is shaped by long development cycles, clinical studies, and capitalized intangible assets, which require judgment on useful lives and impairment. Revenue can also be affected by product/system sales timing, consumables usage, and seasonal demand patterns, making quarterly comparisons uneven. The company’s tax position is also notable because accumulated tax losses are large and deferred tax assets are recognized conservatively. - **Capitalized development costs and patents** — Intangible assets and operating profit - **Revenue recognition on system and consumable sales** — Quarterly revenue mix and gross margin - **Seasonality** — Reported quarterly sales and margins - **Deferred tax assets on loss carryforwards** — Balance sheet and tax expense - Capitalized development and patent assets require amortization judgments - Impairment testing matters if product programs underperform - Revenue timing depends on system deliveries and consumables usage - Seasonality can make quarterly sales comparisons volatile - Deferred tax assets depend on future taxable profits --- *Last updated: 2026-08-11T04:04:51.346877+00:00*